{"id":"W4402552559","doi":"10.1016/j.annonc.2024.08.2330","title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Hexal AG; Pharmacyclics; Genentech; Eisai; Pfizer; Innovent Biologics; Incyte; Moderna; SkylineDx; BeiGene; Les Laboratories Pierre Fabre; Sun Pharma; Regeneron Pharmaceuticals; Array BioPharma; Qbiotics; NGM Biopharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Exelixis; Sanofi; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Ipilimumab; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004371342,0.000152678,0.0005373699,0.000111364,0.00005601531,0.000005648382,0.0001941547,0.000126216,0.0003508837],"category_scores_gemma":[0.0001485759,0.0001050051,0.000397919,0.0002875747,0.0001780065,0.00005689032,0.00005268038,0.0001270633,0.000006891452],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007221654,"about_ca_system_score_gemma":0.0004918315,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007907221,"about_ca_topic_score_gemma":0.0001304891,"domain_scores_codex":[0.9986956,0.00008068111,0.0004887048,0.0002684021,0.0002111234,0.0002555508],"domain_scores_gemma":[0.9987817,0.0003893033,0.0001686063,0.0003894388,0.0002200475,0.00005091539],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.4849184,0.003679943,0.0002360315,0.0004292964,0.002836898,0.00004920513,0.003460707,0.000006308308,0.05266443,0.0005376303,0.05389524,0.3972859],"study_design_scores_gemma":[0.2688699,0.08788957,0.002291539,0.0002752029,0.0008842009,0.00003284321,0.003848188,0.0001363039,0.06122556,0.0002815464,0.5739687,0.0002964378],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854478,0.002779361,0.00002632126,0.003092642,0.001919384,0.001275994,0.00007636872,0.00003476981,0.005347376],"genre_scores_gemma":[0.9964216,0.0002189403,0.00007245052,0.0002565997,0.0001429798,0.00009582729,0.00001575639,0.00002562133,0.002750246],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5200735,"threshold_uncertainty_score":0.4281985,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07706815044565193,"score_gpt":0.4198472869789294,"score_spread":0.3427791365332774,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}